Revenio Group’s fourth quarter results and Financial Statements bulletin 2020 will be published on Thursday, February 11, approximately at 9:00 (EET).
An audiocast and a conference call for analysts and investors, conducted in English, will be held at 15:30 (EET) on the same day.
A link to the audiocast:
https://revenio.videosync.fi/2021-q4-results/register
Dial-in numbers for the conference are:
Finland: +358 981710310
Sweden: +46 856642651
United Kingdom: +44 3333000804
United States: +1 6319131422
PIN code: 34996292#
For further information, please contact:
CEO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
www.revenio.fi
The Revenio Group in brief
Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices and perimeters. The main tools for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).
The Revenio Group comprises Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
In 2019, the Group's net sales totaled EUR 49.5 million, with its operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
REVENIO GROUP OYJ 
